Praxis Precision Stock Extends Rally Premarket As Wall Street Turns Hyper-Bullish After Essential Tremor Trial Win Wall Street boosted the stock’s price targets after the company’s late-stage trial for its essential tremor drug, ulixacaltamide, delivered strong efficacy and safety data.
The 'Groundbreaking' Results That Sent Praxis Precision Medicines Up 200% The company is working on a treatment for essential tremor. Positive results shocked investors following a negative readout in February.
Stay updated with the stocks that are on the move in today's pre-market session. The US market session of Thursday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.
Praxis Precision Medicines Stock Doubles - Here's Why Praxis stock jumps after Phase 3 trials show ulixacaltamide significantly improves essential tremor symptoms and meets key efficacy endpoints.
Praxis' Epilepsy Treatment Shows Promise With Decreased Seizures Praxis Precision Medicines stock fluctuated after reporting mixed results for their drug vormatrigine in treating focal onset seizures.
Praxis Precision Medicines (NASDAQ:PRAX) Posts Q2 2025 Results with Strong Clinical Progress on Vormatrigine Praxis Precision Medicines (PRAX) reports Q2 2025 results, highlighting strong clinical data for epilepsy drug vormatrigine with 56.3% seizure reduction. EPS beats estimates, stock rises pre-market.
Acadia Emerges From Behind The Scenes With A Potential $12 Billion Opportunity Acadia Pharmaceuticals is working on its next-generation Nuplazid and, for CEO Catherine Owen Adams, the journey is personal.
Praxis Precision Medicines 'A Diversified Player In Epilepsy Market,' Analyst Sees Over 100% Stock Upside Chardan initiates Praxis with a Buy rating, highlighting its epilepsy pipeline, strong cash position, and billion-dollar potential of vormatrigine.
Analysts Cut Price Targets For Praxis Precision After Trial Setback For Essential Tremor Candidate Praxis Precision Medicines' ulixacaltamide study for essential tremor faces setback as IDMC recommends stopping for futility. Topline results expected in Q3 2025.
